Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ketamine Biomarker Validation
Sponsor: Soterix Medical
Summary
We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.
Official title: EEG Biomarker Development for Ketamine Administration
Key Details
Gender
All
Age Range
18 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-12-20
Completion Date
2028-03-01
Last Updated
2025-12-29
Healthy Volunteers
No
Conditions
Interventions
Ketamine (0.25 mg/kg)
Low level ketamine infusion therapy.
Ketamine (0.5 mg/kg)
Medium level ketamine infusion therapy.
Ketamine (0.75 mg/kg)
High level ketamine infusion therapy.
Locations (1)
Columbia University Irving Medical Center
New York, New York, United States